Please assess the completion status of the following clinical trial:

Trial Title: A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent by a parent or guardian prior to any study-related procedures.~* When applicable, informed assent (as deemed appropriate by the Institutional Review Board \[IRB\]) by the participant prior to any study-related procedures.~* Participant completed Study SHP633-302 (NCT02980666).~* Participant (and/or parent/guardian) understands and is willing and able to fully adhere to study requirements as defined in this protocol.~Exclusion Criteria:~There are no exclusion criteria for this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teduglutide (Type: EXPERIMENTAL): Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24-week intervals. If a participant deteriorates during a follow-up period, the participant may be evaluated immediately for additional teduglutide treatment (24-week interval) until teduglutide is commercially available for each participant, the participant's participation in this study is discontinued, or the study is discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).